Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

  1. Cortes Castan, J.
  2. Martín, M.
  3. Pernas Simon, S.
  4. Gomez Pardo, P.
  5. Lopez-Tarruella, S.
  6. Gil Martin, M.
  7. Manso, L.M.
  8. Ciruelos, E.M.
  9. Perez Fidalgo, J.A.
  10. Hernando, C.
  11. Ademuyiwa, F.
  12. Weilbaecher, K.
  13. Mayer, I.A.
  14. Pluard, T.
  15. Martinez Garcia, M.
  16. Vahdat, L.T.
  17. Wach, A.
  18. Barker, D.
  19. Romagnoli, B.
  20. Kaufman, P.A.
Aldizkaria:
Annals of oncology : official journal of the European Society for Medical Oncology

ISSN: 1569-8041

Argitalpen urtea: 2018

Alea: 29

Orrialdeak: viii91-viii92

Mota: Artikulua

DOI: 10.1093/ANNONC/MDY272.277 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus